drugset
drugset / Trial / NCT07179081

A Study of AL58805 in Patients With Advanced Tumors

NCT07179081 ↗

Phase 1 Recruiting 40 enrolled Advenchen Laboratories, LLC
NaSingle-groupOpen-labelScreening

Summary

This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and multiple doses, analyzing the tolerance range of multiple doses, observing the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in solid tumor patients, and assessing the reversibility of toxicity and the relationship between toxicity and dose.

Timeline

Start
2020-12-20
Primary completion
2026-01-26
Completion
2026-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject AL58805 Unknown 20 mg Oral
Subject AL58805 Unknown 30 mg Oral
Subject AL58805 Unknown 40 mg Oral
Subject AL58805 Unknown 50 mg Oral
Subject AL58805 Unknown 60 mg Oral

Indications

No indication recorded.